Topic: Health

Scientists at Monash University found a copper-based drug that reduces toxic proteins linked to Alzheimer's and improves memory. The treatment could lead to new therapies for neurovascular dysfunction, a major factor in the disease.

Alzheimer's disease is a major global health challenge. Researchers at Monash University have identified a promising new approach to tackling this condition. A copper-based drug called Cu(ATSM) not only reduced the buildup of toxic proteins linked to Alzheimer's but also improved long-term spatial memory in laboratory studies.

The findings, published in ACS Chemical Neuroscience, suggest that the compound may help restore an important function of the blood-brain barrier. By repairing a key waste-removal system, the treatment could open the door to new therapies aimed at neurovascular dysfunction, a major factor in Alzheimer's disease.

Alzheimer's disease is associated with the accumulation of amyloid-beta, a toxic protein that gradually builds up in the brain. Under normal conditions, these proteins are transported out of the brain and into the bloodstream through the blood-brain barrier. A major part of that process relies on specialized transport proteins known as P-glycoprotein (P-gp) pumps.

In people with Alzheimer's, these pumps become much less effective, reducing the brain's ability to remove harmful waste and allowing amyloid-beta to accumulate. The treatment works by improving the function of the brain's blood vessels, leading to lower levels of toxic proteins and measurable cognitive benefits.

Over 56 days, the treatment reduced toxic amyloid-beta by 42 percent and improved spatial learning by nearly 44 percent. Existing drug candidate Cu(ATSM) may be able to move into human studies relatively quickly because it has already undergone safety testing for other neurological conditions.

Why It Matters

This breakthrough could lead to new treatments for Alzheimer's disease, which is a major global health challenge. With populations aging and dementia-related deaths continuing to rise, researchers say the search for effective treatments that can slow or prevent cognitive decline remains an urgent priority.

Key Facts

• Scientists at Monash University found a copper-based drug called Cu(ATSM) that reduces toxic proteins linked to Alzheimer's disease and improves memory.
• The treatment works by improving the function of the brain's blood vessels, leading to lower levels of toxic proteins and measurable cognitive benefits.
• Over 56 days, the treatment reduced toxic amyloid-beta by 42 percent and improved spatial learning by nearly 44 percent.

Key Terms

Amyloid-beta

A toxic protein that builds up in the brain and is associated with Alzheimer's disease

Implications

This breakthrough could lead to new treatments for Alzheimer's disease, which is a major global health challenge. With populations aging and dementia-related deaths continuing to rise, researchers say the search for effective treatments that can slow or prevent cognitive decline remains an urgent priority.